A collection of essays examining the current status of the therapeutic potential of hallucinogenic substances, exploring how the drugs can be used to effectively treat a wide range of conditions.

This handbook reviews promising applications of psychedelics in treatment of such challenging psychiatric problems as posttraumatic stress disorder, major depression, substance use disorders, and end-of-life anxiety. Experts from multiple disciplines synthesize current knowledge on psilocybin, MDMA, ketamine, and other medical hallucinogens. The volume comprehensively examines these substances' neurobiological mechanisms, clinical effects, therapeutic potential, risks, and anthropological and historical contexts. Coverage ranges from basic science to practical clinical considerations, including patient screening and selection, dosages and routes of administration, how psychedelic-assisted sessions are structured and conducted, and management of adverse reactions.

Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca • Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker. Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago by the U.S. government as well as offering non-technical summaries of the most recent studies with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health. Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field, the growing threat of overmedication by the pharmaceutical industry, and the links between psychiatric drugs and mental illness. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.

This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

Aldous Huxley (1894–1963) was the author of nearly fifty books and numerous essays, best known for his dystopian novel Brave New World. Humphry Osmond (1917–2004) was a British-trained psychiatrist interested in the biological nature of mental illness and the potential for psychedelic drugs to treat psychoses, especially schizophrenia. In 1953, Huxley sent an appreciative note to Osmond about an article he and a colleague had published on their experiments with mescaline, which inspired an initial meeting and decade-long correspondence. This critical edition provides the complete Huxley-Osmond correspondence, chronicling an exchange between two brilliant thinkers who explored such subjects as psychedelics, the visionary experience, the nature of mind, human potentialities, schizophrenia, death and dying, Indigenous rituals and consciousness, socialism, capitalism, totalitarianism, power and authority, and human evolution. There are references to mutual friends, colleagues, and eminent figures of the day, as well as details about both men's personal lives. The letters bear witness to the development of mind-altering drugs aimed at discovering the mechanisms of mental illness and eventually its treatment. A detailed introduction situates the letters in their historical, social, and literary context, explores how Huxley and Osmond first coined the term "psychedelic," contextualizes their work in mid-century psychiatry, and reflects on their legacy as contributors to the science of mind-altering substances. Psychedelic Prophets is an extraordinary record of a full correspondence between two leading minds and a testament to friendship, intellectualism, empathy, and tolerance. The fact that these sentiments emerge so clearly from the letters, at a historical moment best known for polarizing ideological conflict, threats of nuclear war, and the rise of post-modernism, reveals much about the personalities of the authors and the persistence of these themes today.

Psychedelic Drug Treatments: Assisting the Therapeutic Process provides information about current and quite viable investigation into reviving and progressing with neurological research that began in the middle of the 20th century and was brought to a halt when certain drugs were banned in the 1970s. Using a question/answer format, the book will introduce you to the way in which the chemical compounds known as psychedelics affect the brain, provide you with the definitions of key terms particular to the neurological and psychological vocabulary, describe the specific disorders that can realistically be helped or relieved through treatment with psychedelics, and offer information with regard to current research being conducted in the field. This text will discuss the history of the earlier research efforts and will examine the likelihood of a resurgence of interest in the successful development of methods and practices of clinical therapy assisted by psychedelic drugs. The purpose of this volume is to promote an understanding of the use of psychedelics as tools to assist therapy and to challenge the 40-year-old prejudices against research into the possible benefits of these drugs. Features: •Questions and answers about the history, research, and treatments related to psychedelic drugs •Makes a case for the re-evaluation of psychedelics — LSD, MDMA (‘ecstasy’), DMT, psilocybin, ayahuasca, peyote, ibogaine, and more — and their clinical potential for treating a range of conditions from post-traumatic stress disorder and depression to autism and cluster headaches. •Includes numerous in-text resources such as links to Web sites, videos, articles, blogs, etc. from NIH, FDA, YouTube, and university/clinical studies